title: Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.
abstract: The purpose of this study was to better understand the efficacy and safety of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma(R/RMM).
  
  
  
  We retrieved and reviewed published reports including carfilzomib, panobinostat, and elotuzumab combination regimens for patients with R/RMM.
  
  
  
  We identified 20 prospective studies that evaluated 2220 patients. Carfilzomib combination regimens produced an overall response rate (ORR ≥ PR) of 61 % in the 1211 relapsed/refractory patients. At least very good partial response (VGPR) was 29 % in patients with carfilzomib combinations. Finally, 49 % of the 597 patients achieved ORR in patients receiving panobinostat-containing combinations. At least VGPR was 16 % in patients with panobinostat combinations. Three hundred twenty-eight of these 449 patients (73 %) receiving elotuzumab-containing combinations achieved ORR. And at least VGPR was 37 %. And, the vital nonhematologic adverse events (AEs) were cardiac events and pneumonia.
  
  
  
  Carfilzomib, panobinostat, and elotuzumab combination regimens produced clinical benefits in patients with R/RMM.
authors.affiliation: Department of Hematology, Weifang People's Hospital, Weifang, China.
authors.forename: Liping
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Hematology, Weifang People's Hospital, Weifang, China.
authors.forename: Ningning
authors.initials: N
authors.lastname: Zhao
authors.affiliation: Department of Hematology, Weifang People's Hospital, Weifang, China.
authors.forename: Wenjun
authors.initials: W
authors.lastname: Xu
authors.affiliation: Department of Hematology, Weifang People's Hospital, Weifang, China.
authors.forename: Zhixin
authors.initials: Z
authors.lastname: Sheng
authors.affiliation: E.N.T. Department, Weifang People's Hospital, Weifang, China. 452697850@qq.com.
authors.forename: Lida
authors.initials: L
authors.lastname: Wang
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D009842:Oligopeptides / Q000627:therapeutic use; D000077767:Panobinostat; D011014:Pneumonia / Q000139:chemically induced; D011446:Prospective Studies; D016879:Salvage Therapy / Q000009:adverse effects / Q000379:methods*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D006877:Hydroxamic Acids; D007211:Indoles; D009842:Oligopeptides; C546027:elotuzumab; C524865:carfilzomib; D000077767:Panobinostat
keywords: Carfilzomib; Elotuzumab; Multiple myeloma; Panobinostat